23788-74-1

Usage

Uses

Used in Pharmaceutical Industry:
(R)-(-)-2,2-DIMETHYL-1,3-DIOXOLAN-4-YLMETHYL P-TOLUENESULFONATE is used as a key intermediate for the synthesis of antifungal agents, specifically ketoconazole. Its chiral nature allows for the creation of enantiomerically pure compounds, which is essential for the development of effective and safe medications.
Additionally, (R)-(-)-2,2-DIMETHYL-1,3-DIOXOLAN-4-YLMETHYL P-TOLUENESULFONATE is used as a precursor in the preparation of acyclic nucleotide analogs derived from 8-azapurines. These analogs possess antiviral activities and are vital in the development of new antiviral drugs to combat various viral infections.

InChI:InChI=1/C13H18O5S/c1-10-4-6-12(7-5-10)19(14,15)17-9-11-8-16-13(2,3)18-11/h4-7,11H,8-9H2,1-3H3/t11-/m1/s1

Upstream product

• 22323-82-6 (S)-(+)-(2,2-dimethyl-[1,3]dioxolan-4-yl)methanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 1707-77-3 1,2:5,6-di-O-isopropylidene-D-mannitol 
• 102418-34-8 1,2:5,6-bis-O-(1-methylethylidene)-D-mannitol 
• 70987-78-9 (S)-Glycidyl tosylate 
• 67-64-1 acetone 
• 20196-71-8 (2S)-2,3-bis(benzyloxy)propanol 
• 15186-48-8 2,3-isopropylidene-glyceraldehyde 
• 14347-78-5 1,2-O-isopropylidene-D-glycerol 

Downstream Products

• 61267-51-4 (S)-4-(2-methoxy-phenoxymethyl)-2,2-dimethyl-[1,3]dioxolane 
• 139004-01-6 (S)-3-O-(o-Ethoxyphenyl)-1,2-O-isopropyliden-glycerol 
• 93744-25-3 (S)-(+)-4-(2-cyanophenoxy)methyl-2,2-dimethyl-1,3-dioxolane 
• 56969-22-3 C₁₇H₁₄N₂O₂ 
• 65184-36-3 (2S)-1,2-(isopropylidenedioxy)-tridecane 
• 108008-05-5 (R)-(+)-3-<4-<2-(cyclopropylmethoxy)ethyl>phenoxy>-1,2-propanodiol acetonide 
• 62501-66-0 (2S)-3-(2'-benzyloxyphenoxy)-1,2-propanediol acetonide 
• 133242-63-4 2,2-dimethyl-1,3-dioxolan-4R-ylmethyl 3-(4-hydroxyphenyl)propionate 
• 137898-58-9 (S)-2,2-Dimethyl-4-(4-nitro-phenoxymethyl)-[1,3]dioxolane 
• 130998-32-2 (R)-1,2-O-isopropylidene-3-O-(4-methoxyphenyl)glycerol 
• 82966-35-6 (2S,4R)-trans-2-(bromomethyl)-2-(2,4-dichlorophenyl)-4-<<<(4-methylphenyl)sulfonyl>oxy>methyl>-1,3-dioxolane 
• 82966-35-6 (2R,4R)-cis-2-(bromomethyl)-2-(2,4-dichlorophenyl)-4-<<<(4-methylphenyl)sulfonyl>oxy>methyl>-1,3-dioxolane 
• 85564-69-8 (S)-4-((1R,2R,4S)-2-Bicyclo[2.2.1]hept-2-yl-phenoxymethyl)-2,2-dimethyl-[1,3]dioxolane 
• 85564-77-8 (S)-4-((1S,2S,4R)-2-Bicyclo[2.2.1]hept-2-yl-phenoxymethyl)-2,2-dimethyl-[1,3]dioxolane 

Relevant academic research and scientific papers

A Novel Glyceryl Ester (Glyceryl Dendryphiellate A), a Trinor-eremophilane (Dendryphiellin A1), and Eremophilanes (Dendryphiellin E1 and E2) from the Marine Deuteromycete Dendryphiella salina (SUTHERLAND) PUGH et NICOT

Continuing studies of the global extracts from cultures of the marine deuteromycete Dendryphiella salina have led to the isolation of novel compounds that add to the scarce list of marine fungal metabolites.Besides (22E)-ergosta-4,6,8(14),22-tetraen-3-one

Gold(I)-catalyzed, one-pot, oxidative formation of 2,4-disubstituted thiazoles: Application to the synthesis of a pateamine-related macrodiolide

Thiazoles are important heterocyclic motifs in many target molecules. Extension of a reported gold(I)-catalyzed oxidative coupling of alkynes and thioamides to the synthesis of functionalized thiazole-containing products is presented, including the compatibility of this reaction with ester, protected hydroxyl, alkene and thioether groups. The utility of this one-pot process is demonstrated in the preparation of the thiazole-containing macrodiolide of a simplified analogue of pateamine A.

A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration

Neuropathic pain (NP) is a complex chronic pain state with a prevalence of almost 10% in the general population. Pharmacological options for NP are limited and weakly effective, so there is a need to develop more efficacious NP attenuating drugs. Activation of the type 1 lysophosphatidic acid (LPA1) receptor is a crucial factor in the initiation of NP. Hence, it is conceivable that a functional antagonism strategy could lead to NP mitigation. Here we describe a new series of LPA1 agonists among which derivative (S)-17 (UCM-05194) stands out as the most potent and selective LPA1 receptor agonist described so far (Emax = 118%, EC50 = 0.24 μM, KD = 19.6 nM; inactive at autotaxin and LPA2-6 receptors). This compound induces characteristic LPA1-mediated cellular effects and prompts the internalization of the receptor leading to its functional inactivation in primary sensory neurons and to an efficacious attenuation of the pain perception in an in vivo model of NP.

Synthesis and antimicrobial screening of novel 1,3-dioxolanes linked to N-5 of 5H-1,2,4-triazino[5,6-b]indole-3-thiol

Synthesis of 1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-1H-indole-2,3-dione (10) was achieved by coupling 1H-indole-2,3-dione (16) with (R)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-methylbenzenesulfonate (15) in the presence of sodium hydride in dry N,N-dimethylformamide at room temperature in a closed Erlenmeyer flask. Condensation of 10 with hydrazinecarbothioamide in water afforded the thiosemicarbazone derivative 17; its subsequent cyclization with potassium carbonate in water gave the corresponding thione 18 in good yield. The 3-allylthio and 3-benzylthio derivatives 20 and 21 were also prepared by alkylating thiol 19 with alkyl halides in aqueous sodium hydroxide or coupling of 3-(allylthio/benzylthio)-5H-1,2,4-triazino[5,6-b]indoles (23 and 24) with compound 15 in NaH/DMF. Compound 20 was isomerized to a mixture of geometrical isomers (E/Z)-5-[(2,2-dimethyl-1,3-dioxolan-4-yl)-methyl]-3-(prop-1-en-1-ylthio)-5H-1,2,4-triazino[5,6-b]indoles (25 and 26), evidenced by their 1H- and 13C-NMR spectra taken in deuterodimethyl sulfoxide. Structural elucidation of the synthesized compounds was realized using FT-IR, 1H-NMR, 13C-NMR, mass spectrometry and elemental analysis. The newly synthesized compounds were found to possess moderate inhibitory activity against the fungus Candida albicans compared to clotrimazole as reference control. Compounds 10, 17, 19, 20, 21, 23 and 24 had mean growth inhibition zones (IZ) and minimal inhibitory concentrations (MIC) in the range of 12–15 mm and 31.25–200 μg mL-1, respectively, with inhibition levels in the range 70.58–88.23 %. Compound 19 exhibited moderate activity against Gram-positive bacteria Staphylococcus aureus relative to imipenem as the standard drug. All compounds were inactive against Escherichia coli and Pseudomonas aeruginosa.

Compound containing ferrocene base element and preparation method and application of compound

The invention discloses a compound containing a ferrocene base element and a preparation method and application of the compound. A structure formula of the compound containing the ferrocene base element is shown in a formula I. The formula I is shown in the description.

COMPOUNDS AND COMPOSITIONS FOR RADIATION THERAPY AND METHODS OF USING THE SAME

The present disclosure relates to bisphenol ether derivatives and compositions thereof, which can be useful in radiation therapy for treatment of diseases, such as prostate cancer. In particular, the compounds of the present disclosure containing a radiolabeled atom can be useful in targeted delivery of radionuclides for treatment of lesions, tumors, and/or cancer cells.

BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic

Itraconazole (ITZ) is an FDA-approved member of the triazole class of antifungal agents. Two recent drug repurposing screens identified ITZ as a promising anticancer chemotherapeutic that inhibits both the angiogenesis and hedgehog (Hh) signaling pathways. We have synthesized and evaluated first- and second-generation ITZ analogues for their anti-Hh and antiangiogenic activities to probe more fully the structural requirements for these anticancer properties. Our overall results suggest that the triazole functionality is required for ITZ-mediated inhibition of angiogenesis but that it is not essential for inhibition of Hh signaling. The synthesis and evaluation of stereochemically defined des-triazole ITZ analogues also provides key information as to the optimal configuration around the dioxolane ring of the ITZ scaffold. Finally, the results from our studies suggest that two distinct cellular mechanisms of action govern the anticancer properties of the ITZ scaffold.

PROCESS FOR PREPARATION OF PROSTAGLANDIN F2 ALPHA ANALOGUES

A convergent synthesis of the prostaglandin F2α analogues, travoprost and bimatoprost, was developed employing Julia-Lythgoe olefination of the structurally advanced phenylsulfone with an enantiomerically pure aldehyde ω-chain synthon. The novel convergent strategy allows the synthesis of a whole series of prostaglandin analogues of high purity from a common and structurally advanced prostaglandin intermediate.

HALOGENATED COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE

Compounds having a structure of Formula I: (Formula (I)) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R 3, R4, R5, X1, X2, X3 and X4 are as defined herein, and wherein the compound comprises at least one F, CI, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.